XML 42 R31.htm IDEA: XBRL DOCUMENT

Equity (Tables)

9 Months Ended

Sep. 30, 2024

Equity [Abstract]

Schedule of Equity


			Three Months Ended September 30,
			Common Stock						Other Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Loss			Treasury Stock						Non- controlling Interests			Total
($ and shares in millions except per share amounts)			Shares			Par Value												Shares			Cost
Balance at July 1, 2023			3,577			$	1,788		$	44,219		$	54,198		$	(4,900)		1,038			$	(56,612)		$	49		$	38,742
Net income attributable to Merck & Co., Inc.			—			—			—			4,745			—			—			—			—			4,745
Other comprehensive loss, net of taxes			—			—			—			—			(16)			—			—			—			(16)
Cash dividends declared on common stock ($0.73 per share)			—			—			—			(1,861)			—			—			—			—			(1,861)
Treasury stock shares purchased			—			—			—			—			—			4			(466)			—			(466)
Share-based compensation plans and other			—			—			139			—			—			—			12			—			151
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			5			5

Balance at September 30, 2023			3,577			$	1,788		$	44,358		$	57,082		$	(4,916)		1,042			$	(57,066)		$	54		$	41,300
Balance at July 1, 2024			3,577			$	1,788		$	44,362		$	60,187		$	(5,361)		1,041			$	(57,394)		$	66		$	43,648
Net income attributable to Merck & Co., Inc.			—			—			—			3,157			—			—			—			—			3,157
Other comprehensive loss, net of taxes			—			—			—			—			(10)			—			—			—			(10)
Cash dividends declared on common stock ($0.77 per share)			—			—			—			(1,960)			—			—			—			—			(1,960)
Treasury stock shares purchased			—			—			—			—			—			4			(444)			—			(444)
Share-based compensation plans and other			—			—			168			—			—			—			9			—			177
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			4			4
Distributions attributable to noncontrolling interests			—			—			—			—			—			—			—			(12)			(12)
Balance at September 30, 2024			3,577			$	1,788		$	44,530		$	61,384		$	(5,371)		1,045			$	(57,829)		$	58		$	44,560


			Nine Months Ended September 30,
			Common Stock						Other Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Loss			Treasury Stock						Non- controlling Interests			Total
($ and shares in millions except per share amounts)			Shares			Par Value												Shares			Cost
Balance at January 1, 2023			3,577			$	1,788		$	44,379		$	61,081		$	(4,768)		1,039			$	(56,489)		$	67		$	46,058
Net income attributable to Merck & Co., Inc.			—			—			—			1,591			—			—			—			—			1,591
Other comprehensive loss, net of taxes			—			—			—			—			(148)			—			—			—			(148)
Cash dividends declared on common stock ($2.19 per share)			—			—			—			(5,590)			—			—			—			—			(5,590)
Treasury stock shares purchased			—			—			—			—			—			9			(953)			—			(953)
Share-based compensation plans and other			—			—			(21)			—			—			(6)			376			—			355
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			12			12
Distributions attributable to noncontrolling interests			—			—			—			—			—			—			—			(25)			(25)
Balance at September 30, 2023			3,577			$	1,788		$	44,358		$	57,082		$	(4,916)		1,042			$	(57,066)		$	54		$	41,300
Balance at January 1, 2024			3,577			$	1,788		$	44,509		$	53,895		$	(5,161)		1,045			$	(57,450)		$	54		$	37,635
Net income attributable to Merck & Co., Inc.			—			—			—			13,374			—			—			—			—			13,374
Other comprehensive loss, net of taxes			—			—			—			—			(210)			—			—			—			(210)
Cash dividends declared on common stock ($2.31 per share)			—			—			—			(5,885)			—			—			—			—			(5,885)
Treasury stock shares purchased			—			—			—			—			—			7			(817)			—			(817)
Share-based compensation plans and other			—			—			21			—			—			(7)			438			1			460
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			15			15
Distributions attributable to noncontrolling interests			—			—			—			—			—			—			—			(12)			(12)
Balance at September 30, 2024			3,577			$	1,788		$	44,530		$	61,384		$	(5,371)		1,045			$	(57,829)		$	58		$	44,560